牛牛AI助理已提取核心訊息
T2 Biosystems, Inc., a medical diagnostic company, has announced a special meeting of stockholders to be held virtually on April 11, 2024. The primary agenda for the meeting is to seek approval for the conversion of debt to equity with CRG, a healthcare investment firm. This conversion involves issuing shares of common stock or convertible preferred stock in exchange for the cancellation of $15 million of outstanding loans under a term loan agreement with CRG. The conversion price per share will be determined by the lower of the average closing price of T2 Biosystems' common stock on Nasdaq for the five days preceding the issuance or the closing price on the day before issuance. If the conversion results in CRG owning more than 49.99% of T2 Biosystems...Show More
T2 Biosystems, Inc., a medical diagnostic company, has announced a special meeting of stockholders to be held virtually on April 11, 2024. The primary agenda for the meeting is to seek approval for the conversion of debt to equity with CRG, a healthcare investment firm. This conversion involves issuing shares of common stock or convertible preferred stock in exchange for the cancellation of $15 million of outstanding loans under a term loan agreement with CRG. The conversion price per share will be determined by the lower of the average closing price of T2 Biosystems' common stock on Nasdaq for the five days preceding the issuance or the closing price on the day before issuance. If the conversion results in CRG owning more than 49.99% of T2 Biosystems' common stock, convertible preferred stock will be issued instead. The meeting will also address any other business that may properly come before the meeting. Stockholders of record as of March 1, 2024, are entitled to vote at the meeting. The company has distributed proxy materials and encourages stockholders to vote in advance of the meeting.
醫療診斷公司T2 Biosystems, Inc. 宣佈將於2024年4月11日虛擬舉行股東特別會議。會議的主要議程是尋求批准醫療保健投資公司CRG將債務轉換爲股權。這種轉換涉及發行普通股或可轉換優先股，以換取根據與CRG簽訂的定期貸款協議取消1500萬美元的未償貸款。每股轉換價格將由發行前五天T2 Biosystems在納斯達克的普通股的平均收盤價或發行前一天的收盤價中較低者決定。如果轉換導致CRG擁有T2 Biosystems超過49.99％的普通股，則將改爲發行可轉換優先股。會議還將討論可能在會議之前妥善處理的任何其他事項。截至2024年3月1日登記在冊的股東有權在會議上投票。該公司已分發代理材料，並鼓勵股東在會議之前投票。
醫療診斷公司T2 Biosystems, Inc. 宣佈將於2024年4月11日虛擬舉行股東特別會議。會議的主要議程是尋求批准醫療保健投資公司CRG將債務轉換爲股權。這種轉換涉及發行普通股或可轉換優先股，以換取根據與CRG簽訂的定期貸款協議取消1500萬美元的未償貸款。每股轉換價格將由發行前五天T2 Biosystems在納斯達克的普通股的平均收盤價或發行前一天的收盤價中較低者決定。如果轉換導致CRG擁有T2 Biosystems超過49.99％的普通股，則將改爲發行可轉換優先股。會議還將討論可能在會議之前妥善處理的任何其他事項。截至2024年3月1日登記在冊的股東有權在會議上投票。該公司已分發代理材料，並鼓勵股東在會議之前投票。
有用
沒用